{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:53:03Z","timestamp":1787021583096,"version":"build-2736575974"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"S2","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In open studies, bisphosphonate therapy (pamidronate, alendronate) reduced bone pain associated with fibrous dysplasia of bone and was associated to some radiological improvement. Calcium, vitamin D, and phosphorus supplements may be useful in patients with deficiency. We are awaiting results from controlled trials testing bisphosphonates.<\/jats:p>\n                  <jats:p>Introduction: Fibrous dysplasia of bone (FD), a rare disease caused by osteoblastic lineage differentiation defects, is associated with bone pain, fracture, and bone deformity, but few therapeutic options are available.<\/jats:p>\n                  <jats:p>Materials and Methods: We reviewed published data on the treatment of FD with bisphosphonates (pamidronate, alendronate), calcium, vitamin D, and phosphorus. We also present new results on FD therapy with a more potent bisphosphonate, zoledronic acid, given intravenously at the dose of 4 mg every 6 months.<\/jats:p>\n                  <jats:p>Results: Pamidronate therapy, given intravenously every 6 months at a dose of 180 mg in adults, relieved bone pain, decreased bone resorption, and improved the radiological aspect (filling of lytic lesions and\/or thickening of cortices) in \u223c50% of patients. BMD in affected sites was also significantly increased after pamidronate treatment. Those results have been obtained only in open studies, without controls, by several research groups. In a series of nine patients on long-term pamidronate treatment, but resisting to this medication and switched to intravenous zoledronic acid, no substantial improvement was observed. There is some biological rationale supporting the use of calcium and vitamin D in patients with deficiency to improve FD lesions by limiting secondary hyperparathyroidism. Phosphorus supplementation may prevent mineralization defects in those patients who have both FD and renal phosphate wasting. However, we are lacking clinical evidence for the efficacy of such supplements.<\/jats:p>\n                  <jats:p>Conclusions: Bisphosphonate treatment reduces increased osteoclastic activity in FD and probably improves bone pain, but their use should be better studied in randomized controlled trials.<\/jats:p>","DOI":"10.1359\/jbmr.06s222","type":"journal-article","created":{"date-parts":[[2007,1,17]],"date-time":"2007-01-17T16:41:47Z","timestamp":1169052107000},"page":"P114-P119","source":"Crossref","is-referenced-by-count":119,"title":["Medical Therapy in Adults With Fibrous Dysplasia of Bone"],"prefix":"10.1093","volume":"21","author":[{"given":"Roland D","family":"Chapurlat","sequence":"first","affiliation":[{"name":"Department of Rheumatology, INSERM Research Unit 403, and University Claude Bernard, H\u00f4pital E Herriot, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024013019364489500_bib1","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM199112123252403","article-title":"Activating mutations of the stimulatory G protein in the McCune-Albright syndrome","volume":"325","author":"Weinstein","year":"1991","journal-title":"N Engl J Med"},{"key":"2024013019364489500_bib2","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJM199506083322304","article-title":"Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia","volume":"332","author":"Candeliere","year":"1995","journal-title":"N Engl J Med"},{"key":"2024013019364489500_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI118773","article-title":"Increased IL-6 production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome","volume":"98","author":"Yamamoto","year":"1996","journal-title":"J Clin Invest"},{"key":"2024013019364489500_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/(SICI)1096-9896(199901)187:2<249::AID-PATH222>3.0.CO;2-J","article-title":"The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: Site-specific patterns and recurrent histological hallmarks","volume":"187","author":"Riminucci","year":"1999","journal-title":"J Pathol"},{"key":"2024013019364489500_bib5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S8756-3282(03)00064-4","article-title":"Osteoclastogenesis in fibrous dysplasia of bone: In situ and in vitro analysis of IL-6 expression","volume":"33","author":"Riminucci","year":"2003","journal-title":"Bone"},{"key":"2024013019364489500_bib6","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(94)90069-8","article-title":"Long-term effects of intravenous pamidronate in fibrous dysplasia of bone","volume":"343","author":"Liens","year":"1994","journal-title":"Lancet"},{"key":"2024013019364489500_bib7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0002-9343(96)00227-6","article-title":"Biochemical and radiological improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial","volume":"101","author":"Reid","year":"1996","journal-title":"Am J Med"},{"key":"2024013019364489500_bib8","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1359\/jbmr.2003.18.7.1235","article-title":"Osteomalacic and hyperparathyroid changes in fibrous dysplasia of bone: Core biopsy studies and clinical correlations","volume":"18","author":"Corsi","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019364489500_bib9","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1359\/jbmr.2001.16.5.806","article-title":"Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia","volume":"16","author":"Collins","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024013019364489500_bib10","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1359\/jbmr.1997.12.10.1746","article-title":"Long-term effects of intravenous pamidronate in fibrous dysplasia of bone","volume":"12","author":"Chapurlat","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2024013019364489500_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bone.2004.03.004","article-title":"Treatment of fibrous dysplasia of bone with intravenous pamidronate: Predictors of response to treatment and long-term effectiveness","volume":"35","author":"Chapurlat","year":"2004","journal-title":"Bone"},{"key":"2024013019364489500_bib12","first-page":"1","article-title":"The nonsurgical treatment of fibrous dysplasia","volume":"66","author":"Chapurlat","year":"1999","journal-title":"Rev Rhum Engl Ed"},{"key":"2024013019364489500_bib13","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S8756-3282(03)00221-7","article-title":"Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia of bone","volume":"33","author":"Parisi","year":"2003","journal-title":"Bone"},{"key":"2024013019364489500_bib14","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1359\/jbmr.1997.12.8.1314","article-title":"Long-term aminobisphosphonate treatment of fibrous dysplasia: Spectacular increase in bone density","volume":"12","author":"Weinstein","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2024013019364489500_bib15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00776-004-0809-0","article-title":"Oral alendronate treatment for polyostotic fibrous dysplasia: A case report","volume":"9","author":"Kitagawa","year":"2004","journal-title":"J Orthop Sci"},{"key":"2024013019364489500_bib16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00003086-200101000-00003","article-title":"Bisphosphonate therapy in fibrous dysplasia","volume":"382","author":"Lane","year":"2001","journal-title":"Clin Orthop Rel Res"},{"key":"2024013019364489500_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1359\/jbmr.2000.15.1.120","article-title":"Mutations of the GNAS1 gene, stromal cell dysfunction, and ostemalacic changes in non-McCune-Albright fibrous dysplasia of bone","volume":"15","author":"Bianco","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2024013019364489500_bib18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1359\/JBMR.0301262","article-title":"Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome","volume":"19","author":"Leet","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024013019364489500_bib19","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1210\/jc.2003-030050","article-title":"Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone","volume":"88","author":"Plotkin","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019364489500_bib20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1359\/JBMR.041111","article-title":"An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone","volume":"20","author":"Collins","year":"2005","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.06s222","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/21\/S2\/P114\/56478013\/5650211323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/21\/S2\/P114\/56478013\/5650211323.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:48:20Z","timestamp":1710326900000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/21\/S2\/P114-P119\/7593121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,1]]},"references-count":20,"journal-issue":{"issue":"S2","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2006,12,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.06s222","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,12,1]]},"published":{"date-parts":[[2006,12,1]]}}}